Suppression of immunoglobulin synthesis and secretion by peripheral blood lymphocytes from normal donors.
Concanavalin A (Con A)-treated peripheral blood lymphocytes from healthy volunteer donors have been shown to suppress proliferative responses associated with thymus-derived lymphocytes (T-cells). The present investigations demonstrate that peripheral blood lymphocytes incubated with Con A for 48 hr can abrogate pokeweed mitogen-stimulated differentiation of bone-marrow-derived (B) lymphocytes to immunoglobulin-synthesizing and -secreting plasma cells. This effect was manifested when washed Con A-treated peripheral blood lymphocytes were added to pokeweed mitogen-stimulated cocultures containing fresh autologous or allogeneic mononuclear cells, and it did not appear to involve cytotoxicity. Parallel control cultures consisting of mononuclear leukocytes incubated for 48 hr in the absence of Con A also had immunoglobulin suppressor activity in mixing experiments. This effect, however, was most pronounced when preincubated cells were added to fresh autologous pokeweed mitogen-stimulated peripheral blood lymphocytes. Cell mixtures containing peripheral blood lymphocytes demonstrated a spectrum of immunoregulatory effects ranging from suppression to enhancement of pokeweed mitogen-stimulated immunoglobulin synthesis and secretion. Several functional subclasses of suppressor cells that reflect varying levels of specific activity have thus been demonstrated in human beings. Moreover, a degree of genetic identity appears to be required for the expression of "weak" immunoregulatory influences.
D003208:Concanavalin A / Q000494:pharmacology; D006649:Histocompatibility Antigens; D006801:Humans; D007136:Immunoglobulins / Q000096:biosynthesis / Q000378:metabolism*; D007165:Immunosuppression Therapy; D037102:Lectins / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*
D006649:Histocompatibility Antigens; D007136:Immunoglobulins; D037102:Lectins; D003208:Concanavalin A
Eur J Immunol. 1975 Aug;5(8):511-7
61874
J Immunol Methods. 1977;14(1):37-40
833427
Lancet. 1974 Sep 14;2(7881):609-13
4137918
Harvey Lect. 1973;67:273-315
4351100
J Exp Med. 1974 Aug 1;140(2):356-69
4276949
J Clin Invest. 1975 Aug;56(2):467-75
125290
J Immunol. 1976 Jul;117(1):313-8
58934
J Exp Med. 1972 May 1;135(5):1163-76
4623317
Transplant Rev. 1975;27:100-34
52924
J Exp Med. 1973 Jun 1;137(6):1311-24
4541122
J Immunol. 1976 Jan;116(1):167-77
128570
J Exp Med. 1976 May 1;143(5):1100-10
131175
J Exp Med. 1972 Dec 1;136(6):1445-60
4641854
J Exp Med. 1972 May 1;135(5):1133-50
5022177
J Exp Med. 1976 Jul 1;144(1):20-31
1084403
J Clin Invest. 1976 Jul;58(1):109-22
1084353
J Exp Med. 1975 Jun 1;141(6):1390-9
1092799
J Exp Med. 1975 Jun 1;141(6):1376-89
1092798
J Exp Med. 1975 Dec 1;142(6):1436-46
1104746
J Clin Invest. 1976 Feb;57(2):319-28
1082888
J Exp Med. 1976 Jun 1;143(6):1391-40
1083888
J Exp Med. 1976 Jun 1;143(6):1382-90
1083887
J Immunol. 1976 May;116(5):1257-64
1083868
J Exp Med. 1975 Nov 1;142(5):1241-53
1081576
N Engl J Med. 1975 Oct 30;293(18):887-92
1080834
J Exp Med. 1975 Jan 1;141(1):227-41
1078839